PMID- 20880333
OWN - NLM
STAT- MEDLINE
DCOM- 20101215
LR  - 20220408
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 101
IP  - 12
DP  - 2010 Dec
TI  - Retrovirally engineered T-cell-based immunotherapy targeting type III variant 
      epidermal growth factor receptor, a glioma-associated antigen.
PG  - 2518-24
LID - 10.1111/j.1349-7006.2010.01734.x [doi]
AB  - The isotype of epidermal growth factor receptor variant III (EGFRvIII) is often 
      identified in glioblastomas. Previously, we created a mouse monoclonal antibody, 
      3C10 (IgG2b), that specifically recognized EGFRvIII, and a recombinant 
      single-chain variable fragment of 3C10. The aim of the current study was to 
      develop genetically engineered T cells, termed T-bodies, that express a chimeric 
      receptor consisting of the 3C10 single-chain variable fragment coupled to 
      signaling modules such as the CD3zeta (zeta) chain, for the treatment of tumors 
      expressing mutant EGFR. After successful construction of the chimeric 3C10/CD3zeta 
      T-cell receptor, its expression on the T-body was observed using western blotting 
      and flow cytometry. The specificity of the T-body for EGFRvIII was evaluated 
      using an interferon-gamma Elispot assay and a standard (51) Cr-release 
      cytotoxicity assay. Furthermore, we demonstrated that the systemically delivered 
      T-body infiltrated the intrabrain tumor and significantly delayed tumor growth. 
      These results indicate that the T-body expressing the chimeric 3C10/CD3zeta T-cell 
      receptor specifically recognized glioma cells expressing EGFRvIII. In conclusion, 
      T-body-based immunotherapy appears to be a promising approach for the treatment 
      of glioma.
CI  - (c) 2010 Japanese Cancer Association.
FAU - Ohno, Masasuke
AU  - Ohno M
AD  - Department of Neurosurgery, Nagoya University School of Medicine, Nagoya Center 
      for Cell Therapy, Aichi Medical University, Nagakute, Aichi, Japan.
FAU - Natsume, Atsushi
AU  - Natsume A
FAU - Ichiro Iwami, Ken
AU  - Ichiro Iwami K
FAU - Iwamizu, Hidetaka
AU  - Iwamizu H
FAU - Noritake, Kana
AU  - Noritake K
FAU - Ito, Daiki
AU  - Ito D
FAU - Toi, Yuki
AU  - Toi Y
FAU - Ito, Motokazu
AU  - Ito M
FAU - Motomura, Kazuya
AU  - Motomura K
FAU - Yoshida, Jun
AU  - Yoshida J
FAU - Yoshikawa, Kazuhiro
AU  - Yoshikawa K
FAU - Wakabayashi, Toshihiko
AU  - Wakabayashi T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100930
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Single-Chain Antibodies)
RN  - 0 (epidermal growth factor receptor VIII)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology/therapeutic use
MH  - Blotting, Western
MH  - Brain Neoplasms/immunology/*therapy
MH  - Cell Line, Tumor
MH  - Cell Separation
MH  - Enzyme-Linked Immunospot Assay
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Female
MH  - Flow Cytometry
MH  - Genetic Engineering
MH  - Glioma/immunology/*therapy
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Mice
MH  - Mice, SCID
MH  - Receptors, Antigen, T-Cell/genetics/immunology
MH  - Retroviridae
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Single-Chain Antibodies/immunology/therapeutic use
MH  - T-Lymphocytes/*immunology
MH  - Xenograft Model Antitumor Assays
EDAT- 2010/10/01 06:00
MHDA- 2010/12/16 06:00
CRDT- 2010/10/01 06:00
PHST- 2010/10/01 06:00 [entrez]
PHST- 2010/10/01 06:00 [pubmed]
PHST- 2010/12/16 06:00 [medline]
AID - 10.1111/j.1349-7006.2010.01734.x [doi]
PST - ppublish
SO  - Cancer Sci. 2010 Dec;101(12):2518-24. doi: 10.1111/j.1349-7006.2010.01734.x. Epub 
      2010 Sep 30.